Ascendis Pharma Price Target Maintained With a $287.00/Share by Raymond James
Ratings actions from Benzinga: GMT) Ascendis Pharma Cut to Outperform From Strong Buy by Raymond JamesRatings actions from Benzinga
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.